SB 207499

Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… Expand

Among the allergic disorders we emphasize the inflammatory diseases of the inferior respiratory tract by their incidence… Expand

In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a… Expand

The PDE4 catalytic machinery comprises, in part, two divalent cations in a binuclear motif. Here we report that PDE4A4 expressed… Expand

Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… Expand

Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… Expand

The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP… Expand

Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… Expand

We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… Expand

Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept… Expand